Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY, USA.
mBio. 2013 May 7;4(3):e00222-13. doi: 10.1128/mBio.00222-13.
ABSTRACT The chronic nature of tuberculosis (TB), its requirement of long duration of treatment, its ability to evade immune intervention, and its propensity to relapse after drug treatment is discontinued are reminiscent of other chronic, biofilm-associated bacterial diseases. Historically, Mycobacterium tuberculosis was grown as a pellicle, a biofilm-like structure, at the liquid-air interface in a variety of synthetic media. Notably, the most widely administered human vaccine, BCG, is grown as a pellicle for vaccine production. However, the molecular requirements for this growth remain ill defined. Here, we demonstrate that keto-mycolic acids (keto-MA) are essential for pellicle growth, and mutants lacking in or depleted of this MA species are unable to form a pellicle. We investigated the role of the pellicle biofilm in the reduction of antibiotic sensitivity known as drug tolerance using the pellicle-defective ΔmmaA4 mutant strain. We discovered that the ΔmmaA4 mutant, which is both pellicle defective and highly sensitive to rifampicin (RIF) under planktonic growth, when incorporated within the wild-type pellicle biofilm, was protected from the bactericidal activity of RIF. The observation that growth within the M. tuberculosis pellicle biofilm can confer drug tolerance to a drug-hypersensitive strain suggests that identifying molecular requirements for pellicle growth could lead to development of novel interventions against mycobacterial infections. Our findings also suggest that a class of drugs that can disrupt M. tuberculosis biofilm formation, when used in conjunction with conventional antibiotics, has the potential to overcome drug tolerance. IMPORTANCE Two of the most important questions in tuberculosis (TB) research are (i) how does Mycobacterium tuberculosis persist in the human host for decades in the face of an active immune response and (ii) why does it take six months and four drugs to treat uncomplicated TB. Both these aspects of M. tuberculosis biology are reminiscent of infections caused by organisms capable of forming biofilms. M. tuberculosis is capable of growing as a biofilm-like structure called the pellicle. In this study, we demonstrate that a specific cell wall component, keto-mycolic acid, is essential for pellicle growth. We also demonstrate that a strain of M. tuberculosis that is both drug sensitive and pellicle defective exhibits commensal behavior and becomes drug tolerant by becoming part of a heterogeneous pellicle, a characteristic of multispecies biofilms. These observations could have important implications for identifying novel pathways for M. tuberculosis drug tolerance and the design of new modalities to rapidly treat TB.
摘要 结核病(TB)的慢性特征、其长期治疗的需求、其逃避免疫干预的能力以及停药后复发的倾向,都让人联想到其他慢性、生物膜相关的细菌疾病。历史上,结核分枝杆菌作为一种生物膜样结构,在各种合成培养基中在液体-空气界面上生长为菌膜。值得注意的是,应用最广泛的人类疫苗卡介苗(BCG)就是作为菌膜来生产疫苗的。然而,这种生长的分子要求仍然没有明确界定。在这里,我们证明酮基类脂(keto-MA)对于菌膜生长是必不可少的,并且缺乏或耗尽这种 MA 物种的突变体无法形成菌膜。我们研究了生物膜在抗生素敏感性降低方面的作用,这种作用被称为药物耐受性,我们使用了菌膜缺陷型ΔmmaA4 突变株。我们发现,在浮游生长条件下,ΔmmaA4 突变株既不能形成菌膜,而且对利福平(RIF)高度敏感,当它整合到野生型菌膜生物膜中时,它可以免受 RIF 的杀菌活性的影响。在结核分枝杆菌菌膜生物膜内的生长可以赋予药物敏感性菌株药物耐受性的观察结果表明,确定菌膜生长的分子要求可能会导致开发针对分枝杆菌感染的新干预措施。我们的研究结果还表明,当与传统抗生素联合使用时,能够破坏结核分枝杆菌生物膜形成的一类药物有可能克服药物耐受性。 重要性 结核病(TB)研究中最重要的两个问题是:(i)为什么在面对活跃的免疫反应时,结核分枝杆菌能够在人体宿主中持续存在数十年;(ii)为什么治疗单纯性肺结核需要六个月和四种药物。这两个方面都让人联想到能够形成生物膜的病原体引起的感染。结核分枝杆菌能够生长为一种叫做菌膜的生物膜样结构。在这项研究中,我们证明了一种特定的细胞壁成分,酮基类脂酸,对于菌膜生长是必不可少的。我们还证明,一种既敏感又缺乏菌膜的结核分枝杆菌菌株通过成为异质菌膜的一部分表现出共生行为,并通过成为多物种生物膜的特征而变得具有药物耐受性。这些观察结果可能对识别结核分枝杆菌药物耐受性的新途径以及设计快速治疗结核病的新方法具有重要意义。